Covidien Makes Deal With Watson To Allow Generic Exalgo

Law360, New York (January 25, 2012, 7:57 PM EST) -- Zalicus Inc. on Wednesday said Covidien PLC, with which it partners on Covidien's painkiller Exalgo, has agreed to a settlement with Watson Pharmaceuticals Inc. that will allow a generic version of Exalgo to hit the market before the expiration of Covidien's patent.

Under the terms of the settlement between Covidien subsidiary Mallinckrodt Inc. and Watson Pharmaceuticals Inc.-Florida, Watson can introduce a generic version of hydromorphone hydrochloride extended-release tablets on Nov. 15, 2013, several months before the July 7, 2014 expiration of the patent covering the tablets,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.